Epilepsy patients rejoice—AIIMS has launched zero-cost Therapeutic Drug Monitoring (TDM) to perfect medication regimens. This blood test reveals exact anti-epileptic drug concentrations, empowering precise adjustments that save lives.
The need was urgent: In India, 70-80% start treatment successfully, but half discontinue due to inefficacy or toxicity from improper dosing. TDM eliminates trial-and-error, using science for stability.
AIIMS experts spearheading this emphasize accessibility: ‘No more choosing between meals and medicine.’ Integrated into routine neurology visits, testing starts immediately upon referral.
Launch week stats impress: 300+ tests conducted, 60% showing dosage tweaks needed. Follow-ups confirm reduced seizure frequency within weeks.
Government’s push for universal health coverage shines here. Private alternatives? Often ₹3,000+, excluding the poor. AIIMS levels the field.
Community response surges, with neurologists nationwide prescribing TDM proactively. Patient advocate groups praise it as ‘transformative.’
Looking ahead, AIIMS plans mobile units for remote areas. This initiative not only treats epilepsy but redefines public health delivery—efficient, equitable, effective.